ASH 2022: Durable Responses Observed with Mosunetuzumab Monotherapy in Relapsed/Refractory Follicular Lymphoma
ASH 2022: Durable Responses Observed with Mosunetuzumab Monotherapy in Relapsed/Refractory Follicular Lymphoma In research presented by Nancy Bartlett, MD, a past Scientific Advisory Board (SAB) member and LRF grantee, durable clinical responses were observed in patients with relapsed/refractory follicular lymphoma…